Table 1.
Clinical characteristics of patients with cutaneous melanoma (CM, n = 457) in pT stages 1–4.
| Patients with CM | |||||
|---|---|---|---|---|---|
| Characteristics | pT1 (n = 94) | pT2 (n =196) | pT3 (n = 115) | pT4 (n = 52) | Controls (n = 49) |
| Males | 48 (51.1) | 93 (47.5) | 48 (41.7) | 28 (53.9) | 24 (49.0) |
| Median Age (years; P10, P90) | 54 (32; 73) | 58 (34; 74) | 59 (35; 77) | 64 (40; 78) | 61 (33;80) |
| CM subtype | |||||
| Superficial spreading melanoma | 64 (68.1) | 104 (53.1) | 25 (21.7) | 7 (13.5) | |
| Nodular melanoma | 6 (6.4) | 43 (21.9) | 45 (39.1) | 30 (57.7) | |
| Lentigo maligna melanoma | 1 (1.1) | 2 (1.0) | 0 | 0 | |
| Acrolentiginous melanoma | 3 (3.2) | 8 (4.1) | 8 (7.0) | 4 (7.7) | |
| Others | 20 (21.3) | 39 (19.9) | 37 (32.2) | 11 (21.2) | |
| Median tumor thickness, mm (P10, P90) | 0.8 (0.5; 1.0) | 1.4 (1.1; 1.8) | 2.8 (2.1; 3.8) | 5.5 (4.2; 9.8) | |
| Ulceration of primary CM, n (%) | 14 (14.9) | 37 (18.9) | 49 (42.6) | 39 (75.0) | |
| NLR, median (P10, P90) | 2.35 (1.42; 3.86) | 2.30 (1.30; 4.20) | 2.53 (1.30; 4.57) | 2.89 (1.56) | 1.90 (1.1; 11.60) |
| PIV, median (P10, P90) | 268 (138; 586) | 269 (96; 693) | 358 (121; 768) | 421 (136) | 276 (133; 790) |
| CM relapse, n (%) | 9 (9.6) | 39 (19.9) | 47 (40.9) | 33 (63.5) | |
| Median relapse-free survival (months) (P10, P90) | 102 (18; 193) | ||||
| CM-specific death, n (%) | 3 (3.2) | 28 (14.3) | 29 (25.2) | 26 (50.0) | |
| Median CM-specific survival (months) (P10, P90) | 110 (40; 195) | ||||
pT: primary tumor classification; P10 10th percentile, P90: 90th percentile; SSM: superficial spreading; NLR: neutrophil/lymphocyte ratio; PIV: pan-immune inflammation value.